Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).
Alexander Drilon
Stock and Other Ownership Interests: Treeline Bio
Honoraria: Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, Axis, Peerview Institute, Paradigm Medical Communications, WebMD, MJH Life Sciences, Med Learning, Imedex, Answers in CME, Clinical Care Options, EPG Health, JNCC/Harborside, Liberum, Remedica Ltd
Consulting or Advisory Role: Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, Abbvie, 14ner/Elevation Oncology, ArcherDX, Monopteros, Novartis, EMD Serono, Medendi, Repare RX, Nuvalent, Merus, Chugai Pharmaceutical, Remedica Ltd, mBrace, AXIS, EPG Health, Harborside Nexus, Liberum, RV More, Ology, Amgen, TouchIME, Janssen, Entos, Treeline Bio, Prelude, Applied Pharmaceutical Science, Inc, AiCME, i3 Health, MonteRosa
Research Funding: Pfizer (Inst), Exelixis (Inst), GlaxoSmithKlein (Inst), Teva (Inst), Taiho (Inst), PharmaMar (Inst)
Patents, Royalties, Other Intellectual Property: Selpercatinib-Osimertinib (filed/pending), Wolters Kluwer, Merck, Puma, Merus, Boehringer Ingelheim
Vivek Subbiah
Consulting or Advisory Role: MedImmune, Helsinn Therapeutics, Loxo, R-Pharm, QED Therapeutics
Research Funding: Novartis (Inst), GlaxoSmithKline (Inst), NanoCarrier (Inst), Northwest Biotherapeutics (Inst), Genentech/Roche (Inst), Berg Pharma (Inst), Bayer (Inst), Incyte (Inst), Fujifilm (Inst), PharmaMar (Inst), D3 Oncology Solutions (Inst), Pfizer (Inst), AbbVie (Inst), MultiVir (Inst), Blueprint Medicines (Inst), Loxo (Inst), Vegenics (Inst), Takeda (Inst), Alfasigma (Inst), Agensys (Inst), Idera (Inst), Boston Biomedical (Inst), Inhibrx (Inst), Exelixis (Inst), Amgen (Inst), Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses: PharmaMar, Bayer, Novartis, Helsinn Therapeutics
Other Relationship: Medscape
Oliver Gautschi
Consulting or Advisory Role: Amgen (Inst), Lilly (Inst)
Other Relationship: Bayer, Pfizer, Roche, Merck, Lilly
Pascale Tomasini
Consulting or Advisory Role: AstraZeneca, Roche, Bristol Myers Squibb Foundation, Takeda, Amgen, Janssen
Travel, Accommodations, Expenses: Bristol Myers Squibb/Pfizer, AstraZeneca, Takeda
Filippo de Braud
Honoraria: Roche, Pfizer, BMS, Merck, MSD, Servier, Sanofi, Amgen Astellas BioPharma, Incyte
Consulting or Advisory Role: Roche, Incyte, EMD Serono, Bristol Myers Squibb, Nerviano Medical Sciences, Sanofi, Novartis Italy, NMS Medical Science, Menarini, AstraZeneca, Pierre Fabre
Research Funding: Novartis (Inst), Roche (Inst), Merck Serono (Inst), Pfizer (Inst), Servier, Philogen (Inst), Loxo (Inst), Tesaro (Inst), Nerviano Medical Sciences (Inst), Kymab (Inst), Bristol Myers Squibb/Medarex, Merck KGaA, Ignyta, MedImmune, Exelixis, Bayer Health, Daiichi Sankyo Europe GmbH, Incyte, Basilea Pharmaceutical, Janssen Oncology
Benjamin J. Solomon
Honoraria: Bristol Myers Squibb, AstraZeneca, Merck Sharp & Dohme, Roche/Genentech, Pfizer, Amgen (Inst)
Consulting or Advisory Role: Bristol Myers Squibb, Merck Sharp & Dohme, AstraZeneca, Pfizer (Inst), Roche/Genentech, Amgen, Lilly, BeiGene, Takeda, GlaxoSmithKline (Inst), Novartis (Inst), Janssen
Research Funding: Sanofi (Inst)
Patents, Royalties, Other Intellectual Property: UpToDate
Daniel Shao-Weng Tan
Honoraria: Bristol Myers Squibb, Takeda, Novartis, Roche, Pfizer
Consulting or Advisory Role: Novartis, Merck, Loxo, AstraZeneca, Roche, Pfizer, C4 Therapeutics
Research Funding: Novartis (Inst), GlaxoSmithKline (Inst), AstraZeneca (Inst)
Travel, Accommodations, Expenses: Pfizer, Boehringer Ingelheim, Roche
Jürgen Wolf
Honoraria: AbbVie, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, MSD, Novartis, Roche, Amgen, Bayer, Blueprint Medicines, Chugai Pharma Europe, Daiichi Sankyo Europe GmbH, Ignyta, Janssen, Lilly, Loxo, Loxo/Lilly, Pfizer, Seattle Genetics, Takeda
Consulting or Advisory Role: AbbVie, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Chugai Pharma, Ignyta, Lilly, MSD Oncology, Novartis, Pfizer, Roche, Janssen, Loxo/Lilly, Blueprint Medicines, Amgen, Takeda, Bayer, Daiichi Sankyo Europe GmbH, Seattle Genetics
Research Funding: Bristol Myers Squibb, Novartis, Pfizer, Janssen
Keunchil Park
Consulting or Advisory Role: AstraZeneca, Lilly, Ono Pharmaceutical, Bristol Myers Squibb, MSD, Merck KGaA, AbbVie, Daiichi Sankyo, Boehringer Ingelheim, JNJ, IMBdx, Geninus
Speakers' Bureau: Boehringer Ingelheim
Research Funding: AstraZeneca, MSD Oncology
Koichi Goto
Honoraria: Guardant Health, Janssen, Daiichi Sankyo Co Ltd, Amgen, Eisai, Bristol Myers Squibb K.K., AstraZeneca Japan, Chugai Pharma, Ono Pharmaceutical, Novartis, Lilly Japan, Boehringer Ingelheim, Takeda, Otsuka, Amoy Diagnostics, Bayer, Mertck
Consulting or Advisory Role: Takeda, Bayer, Lilly Japan, Amgen, Medpace, Janssen
Research Funding: Medical & Biological Laboratories Co Ltd, Kyowa Kirin Co Ltd, Kissei Pharmaceutical, Merck, Merus, Spectrum Pharmaceuticals, Shanghai HaiHe Pharmaceutical, MSD K.K., AstraZeneca Japan, Taiho Pharmaceutical, Chugai Pharma, Boehringer Ingelheim, Ono Pharmaceutical, Sumitomo Dainippon Pharma Co Ltd, Takeda, Eisai, Lilly Japan, Pfizer, Bristol-Myers Squibb K.K., Ignyta, Janssen, Loxo, Sysmex, Amgen, Thermo Fisher Scientific, Daiichi Sankyo Co Ltd, NEC Corporation, Turning Point Therapeutics
Victoria Soldatenkova
Employment: Lilly
Leadership: Infinity Pharmaceuticals (I)
Stock and Other Ownership Interests: Lilly
Sylwia Szymczak
Employment: Lilly
Stock and Other Ownership Interests: Lilly
Scott S. Barker
Employment: Lilly
Stock and Other Ownership Interests: Lilly
Tarun Puri
Employment: Lilly
Stock and Other Ownership Interests: Lilly
Aimee Bence Lin
Employment: Lilly (I)
Stock and Other Ownership Interests: Lilly (I)
Patents, Royalties, Other Intellectual Property: Co-inventor on a patent application related to selpercatinib activity
Herbert Loong
Consulting or Advisory Role: GlaxoSmithKline, Roche/Genentech, Novartis, Boehringer Ingelheim, Celgene, Lilly, Illumina, Guardant Health, Eisai, Takeda
Speakers' Bureau: Ignyta, Novartis, Guardant Health, Bayer
Research Funding: MSD Oncology (Inst)
Travel, Accommodations, Expenses: Roche, MSD Oncology, Bayer, Pfizer
Benjamin Besse
Research Funding: AstraZeneca (Inst), Pfizer (Inst), Lilly (Inst), Onxeo (Inst), Inivata (Inst), AbbVie (Inst), Amgen (Inst), Blueprint Medicines (Inst), Celgene (Inst), GlaxoSmithKline (Inst), Sanofi (Inst), Takeda (Inst), Cristal Therapeutics (Inst), Daiichi Sankyo (Inst), Janssen Oncology (Inst), OSE Immunotherapeutics (Inst), BeiGene (Inst), Boehringer Ingelheim (Inst), Roche/Genentech (Inst), Tolero Pharmaceuticals (Inst), 4D Pharma (Inst), Aptitude Health (Inst), Cergentis (Inst), Chugai Pharma (Inst), Genzyme (Inst), Ipsen (Inst), Turning Point Therapeutics (Inst), Eisai (Inst)
No other potential conflicts of interest were reported.
留言 (0)